Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The American Journal of Physiology|May 1, 1987
Non-insulin-mediated glucose uptake predominates in postabsorptive dogsM Lavelle-Jones, M H Scott, O Kolterman, et al.
Transplantation|March 1, 1990
Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dogH E Wahlstrom, M Lavelle-Jones, D Endres, et al.
Diabetes, Obesity & Metabolism|November 18, 2003
Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targetsP Hollander, R Ratner, M Fineman, et al.
The American Journal of Physiology|February 1, 1987
Selective suppression of hepatic glucose output by human proinsulin in the dogM Lavelle-Jones, M H Scott, O Kolterman, et al.
Nature|September 13, 1979
A structurally abnormal insulin causing human diabetesH Tager, B Given, D Baldwin, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1984
Biosynthetic human insulin and proinsulin have additive but not synergistic effects on total body glucose disposalR R Revers, R Henry, L Schmeiser, et al.
Diabetes|August 1, 1984
The effects of biosynthetic human proinsulin on carbohydrate metabolismR R Revers, R Henry, L Schmeiser, et al.
Metabolism: Clinical and Experimental|July 27, 1999
The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitusB Nyholm, L Orskov, K Y Hove, et al.
The New England Journal of Medicine|January 17, 1980
Diabetes due to secretion of an abnormal insulinB D Given, M E Mako, H S Tager, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1984
The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetesR M Bergenstal, R M Cohen, E Lever, et al.
Pageof 3